Stryker Co. (NYSE:SYK) Shares Sold by Hancock Whitney Corp

Hancock Whitney Corp decreased its position in shares of Stryker Co. (NYSE:SYK) by 27.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 4,775 shares of the medical technology company’s stock after selling 1,834 shares during the period. Hancock Whitney Corp’s holdings in Stryker were worth $1,625,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Burkett Financial Services LLC acquired a new position in Stryker during the fourth quarter worth approximately $25,000. DSM Capital Partners LLC purchased a new stake in shares of Stryker during the 4th quarter valued at $34,000. Central Pacific Bank Trust Division purchased a new position in shares of Stryker in the 1st quarter worth $39,000. Accent Capital Management LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $60,000. Finally, Sachetta LLC lifted its position in Stryker by 16.3% during the 2nd quarter. Sachetta LLC now owns 242 shares of the medical technology company’s stock worth $80,000 after acquiring an additional 34 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, CFO Glenn S. Boehnlein sold 20,000 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the sale, the chief financial officer now owns 2,852 shares in the company, valued at $949,716. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, VP M Kathryn Fink sold 7,347 shares of Stryker stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total value of $2,696,202.06. Following the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total transaction of $6,660,000.00. Following the sale, the chief financial officer now directly owns 2,852 shares of the company’s stock, valued at $949,716. The disclosure for this sale can be found here. In the last ninety days, insiders sold 220,068 shares of company stock valued at $71,811,372. 5.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on SYK shares. Needham & Company LLC boosted their target price on shares of Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Stifel Nicolaus cut their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a report on Wednesday, July 31st. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a research note on Monday, September 16th. Truist Financial cut their price target on Stryker from $364.00 to $345.00 and set a “hold” rating on the stock in a research note on Thursday, August 1st. Finally, Morgan Stanley increased their price target on Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Five research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $378.58.

Stryker Trading Down 0.1 %

Shares of SYK stock opened at $364.81 on Monday. The firm has a market capitalization of $138.97 billion, a PE ratio of 41.64, a price-to-earnings-growth ratio of 2.87 and a beta of 0.91. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.95 and a current ratio of 1.68. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $374.63. The stock has a fifty day moving average of $345.12 and a two-hundred day moving average of $342.81.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a net margin of 16.12% and a return on equity of 22.89%. The business had revenue of $5.42 billion during the quarter, compared to the consensus estimate of $5.40 billion. During the same quarter in the prior year, the company posted $2.54 earnings per share. The company’s quarterly revenue was up 8.5% compared to the same quarter last year. As a group, research analysts expect that Stryker Co. will post 12 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a $0.80 dividend. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.